Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 441
- Registration Number
- NCT00627445
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00624364
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Richards Bay, South Africa
Metformin in Amnestic Mild Cognitive Impairment
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 80
- Registration Number
- NCT00620191
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 260
- Registration Number
- NCT00619697
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Maribor, Slovenia
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
- Conditions
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2012-12-31
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 1
- Registration Number
- NCT00617058
- Locations
- 🇺🇸
University of North Carolina, Department of Psychiatry, Chapel HIll, North Carolina, United States
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 9
- Registration Number
- NCT00617240
- Locations
- 🇺🇸
University of North Carolina, Department of Psychiatry, Chapel Hill, North Carolina, United States
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 178
- Registration Number
- NCT00614055
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valladolid, Spain
Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 182
- Registration Number
- NCT00613951
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, San Juan, Spain
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 929
- Registration Number
- NCT00614120
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Suwon, Korea, Republic of
Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT00612144
- Locations
- 🇰🇷
Handok Pharmaceuticals, Co., LTD, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.